Thats a Stock called a REAL LIFETIME OPPORTUNITY . Please Do your own DD and you will know why .GL This Unknown Goldmine has two big Products since a few days ago and another three Products will be launched in 2Q 2014 . More Partner Deals coming soon which will bring more Cash to the Company . The Most of the Products targeting a Multi-Billion-Dollar Market . CEO says main goal for 2014 is Nasdaq-Listing means he expect that this Low Float Rocket to move over $3 because this is a requirement for Nasdaq-Listing . At $10 this Stock would have a Market Cap of Only $170 M and thats achievable with their Products which have HUGE Market Potential . Innovus Pharmaceutical (INNV) Market Cap: $7 Million Cash : $1.2 M Price: $0.38 Shares Out : 18.1 Million Float : 10 Million Innovus introduces premature ejaculation drug EjectDelay in US (24 February 2014) http://otc.pharmaceutical-business-...culation-drug-ejectdelay-in-us-240214-4183187 Monster Pipeline : Product Route Stage Disease Territory Exp.Launch Date CIRCUMserum™ Topical OTC Reduced Penile Sensitivity Ex-US Marketed EjectDelay™ Topical OTC Compliant Premature Ejaculation Worldwide Q1 2014 Apeaz™ Topical OTC Compliant Arthritis Pain Worldwide Q1 2014 Acne Care Topical OTC Registration Acne Treatment Worldwide Q2 2014 Cough/Cold Lozenges Oral OTC Cough & Cold Reduction Worldwide Q2 1014 Xyralid™ Topical OTC Registration Anesthetic Worldwide Q2 2014 ----- CEO holding over 6 Mil shrs thats almost 35% of the 18 M Shrs Outstanding and he currently financing the Company with his own money . Its always a good sign when CEO support the Company like this way . http://data.cnbc.com/quotes/INNV/tab/8 Major Shareholders of Innovus ( Shares Outstanding : 18.1 M ) : Damaj (Bassam B) ... 6.2M Esber (Henry Jemil) ...2.5M Quaker Partners ...1.6M Liu (Vivian H) .....990.9K Jadra (Ramon) .....989.2K Boyack (Wallace) ....840.6K Mirza (Ziad) ....429.2K Info about the CEO : Damaj took the reins of Innovus as CEO in January, 2013. In his previous position at Apricus Biosciences, the market cap of Apricus grew from $17 million to more than $100 million. During Damaj's tenure at Apricus,partnerships were signed with companies such as Abbott, Sandoz, and Takeda http://www.news-medical.net/news/20...th-Dr-Bassam-Damaj-CEO-of-Innovus-Pharma.aspx [h=2]What excites you the most about Innovus’ product pipeline right now?[/h] Innovus has built an impressive commercial pipeline in a very short period of time. I am excited about the fact that we have the product which will allow us to do commercial partnerships and start generating revenues for the company. [h=2]How strong is the market for these products predicted to be over the next 3-5 years?[/h] Our products are for diseases in the sexual dysfunction, dermatology, respiratory and inflammation/pain areas. Those are big markets and the number of patients is on the rise year after year. [h=2]What are Innovus’ plans for the future?[/h] Innovus’ plans are very clear and focused. We are working towards commercial partnerships for our product to start generating revenues on a worldwide basis towards our main goal of listing the company on Nasdaq in 2014.